IPO Timeline
Broker Results (T-2)
2020-11-18
Some brokers release in afternoon
Grey Market (T-1)
2020-11-19
Afternoon
HKEX Allotment (T-1)
2020-11-19
Evening
Registrar Allotment (T-1)
2020-11-19
Evening
Listing Day (T)
2020-11-20
First day of trading
Company Overview
| Stock Name | 德琪醫藥有限公司 - B |
|---|---|
| Stock Code | 06996 |
| Company Full Name | 德琪醫藥有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注於抗腫瘤藥物。 |
| Listing Date | 2020-11-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市長寧區中山西路1065號SOHO中山廣場B座1206-1209室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.antengene.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 18.08 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 49.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,393,552,160 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 18.28 |
|---|---|
| First Day Open | HK$ 19.6 |
| First Day Change | 1.11% |
| First Day Volume | 62460700.0 |
| First Day Turnover | 1182990000.0 |
Use of Proceeds
| Use of Proceeds | 1、約1,071.1百萬港元（占所得款項凈額的41%）將分配予核心產品； 2、約654.4百萬港元（占所得款項凈額的25%）將用于為我們的其他四種臨床階段候選藥物提供資金； 3、約248.9百萬港元（占所得款項凈額的9%）預計將用于本公司管線中的其他臨床前候選藥物正在進行的臨床前研究及計劃進行的臨床試驗； 4、約359.7百萬港元（占所得款項凈額的14%）預計將用于擴大本公司的研發管線，包括發現新的候選藥物及業務開發活動； 5、約38.2百萬港元（占所得款項凈額的1%）預計將用于資本開支； 6、約263.6百萬港元（占所得款項凈額的10%）預計將用于一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Far East) Limited CE AAB026
Overall Coordinators (4)
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (5)
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
招银国际融资有限公司 CE AVM940
Joint Lead Managers (6)
高盛（亚洲）有限责任公司 CE ACC536
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
招银国际融资有限公司 CE AVM940
富途证券国际（香港）有限公司 CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds | 116,254,400 HKD | — | 4.17% | — | 6 months | 2021-05-20 |
| 2 | Boyu Capital Opportunities Master Fund | 116,254,400 HKD | — | 4.17% | — | 6 months | 2021-05-20 |
| 3 | Cormorant Asset Management, LP | 116,254,400 HKD | — | 4.17% | — | 6 months | 2021-05-20 |
| 4 | CRF Investment Holdings Company Limited | 37,199,600 HKD | — | 1.33% | — | 6 months | 2021-05-20 |
| 5 | Fidelity International | 542,544,640 HKD | — | 19.47% | — | 6 months | 2021-05-20 |
| 6 | GIC Private Limited | 155,008,880 HKD | — | 5.56% | — | 6 months | 2021-05-20 |
| 7 | Hillhouse Funds | 116,254,400 HKD | — | 4.17% | — | 6 months | 2021-05-20 |
| 8 | Laurion Capital Master Fund, Ltd. | 37,199,600 HKD | — | 1.33% | — | 6 months | 2021-05-20 |
| 9 | Octagon Investments Master Fund LP | 37,199,600 HKD | — | 1.33% | — | 6 months | 2021-05-20 |
| 10 | SCC Growth VI Holdco F, Ltd. | 116,254,400 HKD | — | 4.17% | — | 6 months | 2021-05-20 |
Directors & Management
| Chairman | 梅建明 |
|---|---|
| Company Secretary | 曹洋;黃偉超 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 梅建明及家族成員(26.48%);Boyu Capital Fund III, L.P.(9.44%);FV Begonia Partners, L.P(7.01%);Qiming Corporate GP V, Ltd(6.05%) |
|---|
IPO Timeline
